Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | fms-related tyrosine kinase 4 | Starlite/ChEMBL | References |
Homo sapiens | fms-related tyrosine kinase 1 | Starlite/ChEMBL | References |
Homo sapiens | colony stimulating factor 1 receptor | Starlite/ChEMBL | References |
Homo sapiens | platelet-derived growth factor receptor, alpha polypeptide | Starlite/ChEMBL | References |
Homo sapiens | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Starlite/ChEMBL | References |
Homo sapiens | fms-related tyrosine kinase 3 | Starlite/ChEMBL | References |
Homo sapiens | ret proto-oncogene | Starlite/ChEMBL | References |
Homo sapiens | kinase insert domain receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | TK/KIN16 protein kinase | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Echinococcus granulosus | macrophage colony stimulating factor 1 receptor | Get druggable targets OG5_132967 | All targets in OG5_132967 |
Onchocerca volvulus | Get druggable targets OG5_130320 | All targets in OG5_130320 | |
Onchocerca volvulus | Tyrosine kinase homolog | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Brugia malayi | Immunoglobulin I-set domain containing protein | Get druggable targets OG5_130320 | All targets in OG5_130320 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0365 | 0.2517 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.016 | 0.025 |
Plasmodium falciparum | cytochrome b | 0.0401 | 0.2851 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0365 | 0.2517 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0365 | 0.2517 | 0.5 |
Toxoplasma gondii | apocytochrome b, putative | 0.0401 | 0.2851 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.016 | 0.025 |
Brugia malayi | cytochrome b | 0.0401 | 0.2851 | 0.1122 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0365 | 0.2517 | 0.5 |
Echinococcus granulosus | roundabout 2 | 0.0109 | 0.016 | 0.016 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0365 | 0.2517 | 0.5 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0365 | 0.2517 | 0.5 |
Echinococcus multilocularis | roundabout 2 | 0.0109 | 0.016 | 1 |
Onchocerca volvulus | Tyrosine kinase homolog | 0.0609 | 0.4762 | 1 |
Wolbachia endosymbiont of Brugia malayi | cytochrome b subunit of the bc complex | 0.0401 | 0.2851 | 0.5 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0688 | 0.5493 | 1 |
Schistosoma mansoni | cytochrome b | 0.0401 | 0.2851 | 1 |
Loa Loa (eye worm) | cytochrome b | 0.0401 | 0.2851 | 0.5169 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0688 | 0.5493 | 1 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0365 | 0.2517 | 0.5 |
Toxoplasma gondii | cytochrome b | 0.0401 | 0.2851 | 1 |
Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0094 | 0.0024 | 0.0024 |
Loa Loa (eye worm) | hypothetical protein | 0.0365 | 0.2517 | 0.4559 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0365 | 0.2517 | 0.5 |
Echinococcus granulosus | cytochrome B | 0.0401 | 0.2851 | 0.2851 |
Mycobacterium ulcerans | hypothetical protein | 0.0365 | 0.2517 | 0.5 |
Schistosoma mansoni | cytochrome b | 0.0401 | 0.2851 | 1 |
Plasmodium vivax | cytochrome b | 0.0401 | 0.2851 | 0.5 |
Schistosoma mansoni | cell adhesion molecule | 0.0094 | 0.0024 | 0.0083 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AUC (ADMET) | = 6114 ng.hr/ml | AUC in BALB/c mouse at 2 mg/kg, iv | ChEMBL. | 21316232 |
AUC (ADMET) | = 12305 ng.hr/ml | AUC in BALB/c mouse at 10 mg/kg, po | ChEMBL. | 21316232 |
CL (ADMET) | = 5.6 ml/min.kg | Clearance in BALB/c mouse at 2 mg/kg, iv | ChEMBL. | 21316232 |
Cmax (ADMET) | = 2786 ng/ml | Cmax in BALB/c mouse at 10 mg/kg, po | ChEMBL. | 21316232 |
Cmax (ADMET) | = 2987 ng/ml | Cmax in BALB/c mouse at 2 mg/kg, iv | ChEMBL. | 21316232 |
F (ADMET) | = 16 % | Oral bioavailability in BALB/c mouse at 10 mg/kg | ChEMBL. | 21316232 |
IC50 (binding) | = 11 nM | Inhibition of VEGFR2 | ChEMBL. | 21316232 |
IC50 (binding) | = 183 nM | Inhibition of RET | ChEMBL. | 21316232 |
IC50 (binding) | = 513 nM | Inhibition of KIT | ChEMBL. | 21316232 |
IC50 (binding) | = 622 nM | Inhibition of CSF1R | ChEMBL. | 21316232 |
IC50 (binding) | = 1100 nM | Inhibition of FLT4 | ChEMBL. | 21316232 |
IC50 (binding) | = 1110 nM | Inhibition of PDGFRalpha | ChEMBL. | 21316232 |
IC50 (binding) | = 4420 nM | Inhibition of FLT1 | ChEMBL. | 21316232 |
IC50 (binding) | = 4800 nM | Inhibition of FLT3 | ChEMBL. | 21316232 |
Inhibition (functional) | = 90 % | Antitumor activity against human A431 cells xenografted mouse model measured at 100 to 200 mg/kg, po after 10 to 14 days | ChEMBL. | 21316232 |
Inhibition (functional) | = 90 % | Antitumor activity against human HCT116 cells xenografted mouse model measured at 100 to 200 mg/kg, po after 10 to 14 days | ChEMBL. | 21316232 |
Inhibition (functional) | = 90 % | Antitumor activity against human A375 cells xenografted mouse model assessed as growth inhibition at 100 mg/kg, po | ChEMBL. | 21316232 |
T1/2 (ADMET) | = 2.1 hr | Half life in BALB/c mouse at 10 mg/kg, po | ChEMBL. | 21316232 |
T1/2 (ADMET) | = 2.8 hr | Half life in BALB/c mouse at 2 mg/kg, iv | ChEMBL. | 21316232 |
Vdss (ADMET) | = 0.7 L/Kg | Volume of distribution at steady state in BALB/c mouse at 2 mg/kg, iv | ChEMBL. | 21316232 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.